http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Sep 2025 08:05:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html <p align="left">FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.</p> <p>“We are excited to present our poster at http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html Wed, 03 Sep 2025 08:05:00 -0500 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html <p align="left">FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.</p> <p>“We are excited to present our poster at http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html Wed, 03 Sep 2025 08:05:00 -0500 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html <p align="left">FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.</p> <p>“We are excited to present our poster at http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html Wed, 03 Sep 2025 08:05:00 -0500 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html <p align="left">FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.</p> <p>“We are excited to present our poster at http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html Wed, 03 Sep 2025 08:05:00 -0500 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html <p align="left">FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.</p> <p>“We are excited to present our poster at http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html Wed, 03 Sep 2025 08:05:00 -0500 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html <p align="left">FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.</p> <p>“We are excited to present our poster at http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html Wed, 03 Sep 2025 08:05:00 -0500 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html <p align="left">FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.</p> <p>“We are excited to present our poster at http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html Wed, 03 Sep 2025 08:05:00 -0500 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html <p align="left">FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.</p> <p>“We are excited to present our poster at http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+to+Present+Data+in+Poster+Presentation+at+the+American+Association+for+Cancer+Research+Special+Conference+on+Advances+in+Pancreatic+Cancer+Research/25288783.html Wed, 03 Sep 2025 08:05:00 -0500 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html <p align="center"><em>Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway</em></p> <p align="center"><em>Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025</em></p> <p align="center"><em>On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025</em></p> <p align="center"><em>Company to Hold Webcast and Conference Call at 8:30 AM ET Today</em></p> <p>FLORHAM PARK, N.J., Aug. http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html Thu, 14 Aug 2025 07:19:00 -0500 A.31066700 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html <p align="center"><em>Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway</em></p> <p align="center"><em>Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025</em></p> <p align="center"><em>On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025</em></p> <p align="center"><em>Company to Hold Webcast and Conference Call at 8:30 AM ET Today</em></p> <p>FLORHAM PARK, N.J., Aug. http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html Thu, 14 Aug 2025 07:19:00 -0500 A.31066700 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html <p align="center"><em>Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway</em></p> <p align="center"><em>Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025</em></p> <p align="center"><em>On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025</em></p> <p align="center"><em>Company to Hold Webcast and Conference Call at 8:30 AM ET Today</em></p> <p>FLORHAM PARK, N.J., Aug. http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html Thu, 14 Aug 2025 07:19:00 -0500 A.31066700 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html <p align="center"><em>Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway</em></p> <p align="center"><em>Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025</em></p> <p align="center"><em>On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025</em></p> <p align="center"><em>Company to Hold Webcast and Conference Call at 8:30 AM ET Today</em></p> <p>FLORHAM PARK, N.J., Aug. http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html Thu, 14 Aug 2025 07:19:00 -0500 A.31066700 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html <p align="center"><em>Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway</em></p> <p align="center"><em>Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025</em></p> <p align="center"><em>On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025</em></p> <p align="center"><em>Company to Hold Webcast and Conference Call at 8:30 AM ET Today</em></p> <p>FLORHAM PARK, N.J., Aug. http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html Thu, 14 Aug 2025 07:19:00 -0500 A.31066700 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html <p align="center"><em>Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway</em></p> <p align="center"><em>Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025</em></p> <p align="center"><em>On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025</em></p> <p align="center"><em>Company to Hold Webcast and Conference Call at 8:30 AM ET Today</em></p> <p>FLORHAM PARK, N.J., Aug. http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html Thu, 14 Aug 2025 07:19:00 -0500 A.31066700 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html <p align="center"><em>Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway</em></p> <p align="center"><em>Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025</em></p> <p align="center"><em>On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025</em></p> <p align="center"><em>Company to Hold Webcast and Conference Call at 8:30 AM ET Today</em></p> <p>FLORHAM PARK, N.J., Aug. http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html Thu, 14 Aug 2025 07:19:00 -0500 A.31066700 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html <p align="center"><em>Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway</em></p> <p align="center"><em>Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025</em></p> <p align="center"><em>On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025</em></p> <p align="center"><em>Company to Hold Webcast and Conference Call at 8:30 AM ET Today</em></p> <p>FLORHAM PARK, N.J., Aug. http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html Thu, 14 Aug 2025 07:19:00 -0500 A.31066700 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html <p align="center"><em>Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway</em></p> <p align="center"><em>Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025</em></p> <p align="center"><em>On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025</em></p> <p align="center"><em>Company to Hold Webcast and Conference Call at 8:30 AM ET Today</em></p> <p>FLORHAM PARK, N.J., Aug. http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html Thu, 14 Aug 2025 07:19:00 -0500 A.31066700 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html <p align="center"><em>Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway</em></p> <p align="center"><em>Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025</em></p> <p align="center"><em>On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025</em></p> <p align="center"><em>Company to Hold Webcast and Conference Call at 8:30 AM ET Today</em></p> <p>FLORHAM PARK, N.J., Aug. http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+Second+Quarter+2025+Financial+Results+and+Provides+a+Corporate+Update/25200264.html Thu, 14 Aug 2025 07:19:00 -0500 A.31066700 CLRB CLRBW CLRBZ O.21558387 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html <p align="left">FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows:</p> <p>Date: Monday, March 17<br/>Time: 8:30 AM Eastern Time<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1ZdoX0VJhF05x5qvD_hG92P0wY98Lh3E8jck5ArC9_7hAAoNych2CEoMjoeBfGSXf4VWNBBhe3Htu2Y4nudTZ3ffuMNgHmOAsmfR_p06-hm-xNPIt3XlOoPXMSKQ7zGK7ywaZhsvbDDAhsRObJpJJslQn9IYw_ZjRvzKg_36aMM=" rel="nofollow" target="_blank">Click HERE</a></p> <p>A replay of the corporate presentation will be available on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9PiiqOGXEaP2O_Zy49a5N1ubdMuL0N7APC8JoivX80HVyputol5j0Is2mp4Y2ssQCex9FYo4VW12RvDSGzYN_Jwmkzmd4x3jxvp_PArORCg=" rel="nofollow" target="_blank">Events</a> section of the company’s <a target="_blank" href="https://www.globenewswire.com/Tracker?data=HWXESYFD_fPdSZO51PQ1_IX-gqeqxWUtwoa4xHkoHzWuScxAbeRnuqYdZTmn6tus2GvcKW5fG7pJnS4Uh32U5FpTFMKUaJcV8p7N3YdS568=" rel="nofollow" target="_blank">Investor http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html Tue, 11 Mar 2025 08:05:00 -0500 A.50213550 CLRB CLRBW CLRBZ O.21558387 O.35229939 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html <p align="left">FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows:</p> <p>Date: Monday, March 17<br/>Time: 8:30 AM Eastern Time<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1ZdoX0VJhF05x5qvD_hG92P0wY98Lh3E8jck5ArC9_7hAAoNych2CEoMjoeBfGSXf4VWNBBhe3Htu2Y4nudTZ3ffuMNgHmOAsmfR_p06-hm-xNPIt3XlOoPXMSKQ7zGK7ywaZhsvbDDAhsRObJpJJslQn9IYw_ZjRvzKg_36aMM=" rel="nofollow" target="_blank">Click HERE</a></p> <p>A replay of the corporate presentation will be available on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9PiiqOGXEaP2O_Zy49a5N1ubdMuL0N7APC8JoivX80HVyputol5j0Is2mp4Y2ssQCex9FYo4VW12RvDSGzYN_Jwmkzmd4x3jxvp_PArORCg=" rel="nofollow" target="_blank">Events</a> section of the company’s <a target="_blank" href="https://www.globenewswire.com/Tracker?data=HWXESYFD_fPdSZO51PQ1_IX-gqeqxWUtwoa4xHkoHzWuScxAbeRnuqYdZTmn6tus2GvcKW5fG7pJnS4Uh32U5FpTFMKUaJcV8p7N3YdS568=" rel="nofollow" target="_blank">Investor http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html Tue, 11 Mar 2025 08:05:00 -0500 A.50213550 CLRB CLRBW CLRBZ O.21558387 O.35229939 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html <p align="left">FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows:</p> <p>Date: Monday, March 17<br/>Time: 8:30 AM Eastern Time<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1ZdoX0VJhF05x5qvD_hG92P0wY98Lh3E8jck5ArC9_7hAAoNych2CEoMjoeBfGSXf4VWNBBhe3Htu2Y4nudTZ3ffuMNgHmOAsmfR_p06-hm-xNPIt3XlOoPXMSKQ7zGK7ywaZhsvbDDAhsRObJpJJslQn9IYw_ZjRvzKg_36aMM=" rel="nofollow" target="_blank">Click HERE</a></p> <p>A replay of the corporate presentation will be available on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9PiiqOGXEaP2O_Zy49a5N1ubdMuL0N7APC8JoivX80HVyputol5j0Is2mp4Y2ssQCex9FYo4VW12RvDSGzYN_Jwmkzmd4x3jxvp_PArORCg=" rel="nofollow" target="_blank">Events</a> section of the company’s <a target="_blank" href="https://www.globenewswire.com/Tracker?data=HWXESYFD_fPdSZO51PQ1_IX-gqeqxWUtwoa4xHkoHzWuScxAbeRnuqYdZTmn6tus2GvcKW5fG7pJnS4Uh32U5FpTFMKUaJcV8p7N3YdS568=" rel="nofollow" target="_blank">Investor http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html Tue, 11 Mar 2025 08:05:00 -0500 A.50213550 CLRB CLRBW CLRBZ O.21558387 O.35229939 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html <p align="left">FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows:</p> <p>Date: Monday, March 17<br/>Time: 8:30 AM Eastern Time<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1ZdoX0VJhF05x5qvD_hG92P0wY98Lh3E8jck5ArC9_7hAAoNych2CEoMjoeBfGSXf4VWNBBhe3Htu2Y4nudTZ3ffuMNgHmOAsmfR_p06-hm-xNPIt3XlOoPXMSKQ7zGK7ywaZhsvbDDAhsRObJpJJslQn9IYw_ZjRvzKg_36aMM=" rel="nofollow" target="_blank">Click HERE</a></p> <p>A replay of the corporate presentation will be available on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9PiiqOGXEaP2O_Zy49a5N1ubdMuL0N7APC8JoivX80HVyputol5j0Is2mp4Y2ssQCex9FYo4VW12RvDSGzYN_Jwmkzmd4x3jxvp_PArORCg=" rel="nofollow" target="_blank">Events</a> section of the company’s <a target="_blank" href="https://www.globenewswire.com/Tracker?data=HWXESYFD_fPdSZO51PQ1_IX-gqeqxWUtwoa4xHkoHzWuScxAbeRnuqYdZTmn6tus2GvcKW5fG7pJnS4Uh32U5FpTFMKUaJcV8p7N3YdS568=" rel="nofollow" target="_blank">Investor http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html Tue, 11 Mar 2025 08:05:00 -0500 A.50213550 CLRB CLRBW CLRBZ O.21558387 O.35229939 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html <p align="left">FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows:</p> <p>Date: Monday, March 17<br/>Time: 8:30 AM Eastern Time<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1ZdoX0VJhF05x5qvD_hG92P0wY98Lh3E8jck5ArC9_7hAAoNych2CEoMjoeBfGSXf4VWNBBhe3Htu2Y4nudTZ3ffuMNgHmOAsmfR_p06-hm-xNPIt3XlOoPXMSKQ7zGK7ywaZhsvbDDAhsRObJpJJslQn9IYw_ZjRvzKg_36aMM=" rel="nofollow" target="_blank">Click HERE</a></p> <p>A replay of the corporate presentation will be available on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9PiiqOGXEaP2O_Zy49a5N1ubdMuL0N7APC8JoivX80HVyputol5j0Is2mp4Y2ssQCex9FYo4VW12RvDSGzYN_Jwmkzmd4x3jxvp_PArORCg=" rel="nofollow" target="_blank">Events</a> section of the company’s <a target="_blank" href="https://www.globenewswire.com/Tracker?data=HWXESYFD_fPdSZO51PQ1_IX-gqeqxWUtwoa4xHkoHzWuScxAbeRnuqYdZTmn6tus2GvcKW5fG7pJnS4Uh32U5FpTFMKUaJcV8p7N3YdS568=" rel="nofollow" target="_blank">Investor http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html Tue, 11 Mar 2025 08:05:00 -0500 A.50213550 CLRB CLRBW CLRBZ O.21558387 O.35229939 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html <p align="left">FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows:</p> <p>Date: Monday, March 17<br/>Time: 8:30 AM Eastern Time<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1ZdoX0VJhF05x5qvD_hG92P0wY98Lh3E8jck5ArC9_7hAAoNych2CEoMjoeBfGSXf4VWNBBhe3Htu2Y4nudTZ3ffuMNgHmOAsmfR_p06-hm-xNPIt3XlOoPXMSKQ7zGK7ywaZhsvbDDAhsRObJpJJslQn9IYw_ZjRvzKg_36aMM=" rel="nofollow" target="_blank">Click HERE</a></p> <p>A replay of the corporate presentation will be available on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9PiiqOGXEaP2O_Zy49a5N1ubdMuL0N7APC8JoivX80HVyputol5j0Is2mp4Y2ssQCex9FYo4VW12RvDSGzYN_Jwmkzmd4x3jxvp_PArORCg=" rel="nofollow" target="_blank">Events</a> section of the company’s <a target="_blank" href="https://www.globenewswire.com/Tracker?data=HWXESYFD_fPdSZO51PQ1_IX-gqeqxWUtwoa4xHkoHzWuScxAbeRnuqYdZTmn6tus2GvcKW5fG7pJnS4Uh32U5FpTFMKUaJcV8p7N3YdS568=" rel="nofollow" target="_blank">Investor http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html Tue, 11 Mar 2025 08:05:00 -0500 A.50213550 CLRB CLRBW CLRBZ O.21558387 O.35229939 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html <p align="left">FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows:</p> <p>Date: Monday, March 17<br/>Time: 8:30 AM Eastern Time<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1ZdoX0VJhF05x5qvD_hG92P0wY98Lh3E8jck5ArC9_7hAAoNych2CEoMjoeBfGSXf4VWNBBhe3Htu2Y4nudTZ3ffuMNgHmOAsmfR_p06-hm-xNPIt3XlOoPXMSKQ7zGK7ywaZhsvbDDAhsRObJpJJslQn9IYw_ZjRvzKg_36aMM=" rel="nofollow" target="_blank">Click HERE</a></p> <p>A replay of the corporate presentation will be available on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9PiiqOGXEaP2O_Zy49a5N1ubdMuL0N7APC8JoivX80HVyputol5j0Is2mp4Y2ssQCex9FYo4VW12RvDSGzYN_Jwmkzmd4x3jxvp_PArORCg=" rel="nofollow" target="_blank">Events</a> section of the company’s <a target="_blank" href="https://www.globenewswire.com/Tracker?data=HWXESYFD_fPdSZO51PQ1_IX-gqeqxWUtwoa4xHkoHzWuScxAbeRnuqYdZTmn6tus2GvcKW5fG7pJnS4Uh32U5FpTFMKUaJcV8p7N3YdS568=" rel="nofollow" target="_blank">Investor http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+to+Present+at+the+37th+Annual+Roth+Conference/24481443.html Tue, 11 Mar 2025 08:05:00 -0500 A.50213550 CLRB CLRBW CLRBZ O.21558387 O.35229939